EU/3/14/1289:

Recombinant human alpha-1-microglobulin

Overview

Please note that this product was withdrawn from the Union Register of orphan medicinal products in May 2021 on request of the Sponsor.

On 4 July 2014, orphan designation (EU/3/14/1289) was granted by the European Commission to A1M Pharma AB, Sweden, for recombinant human alpha-1-microglobulin for the treatment of pre‑eclampsia.

In April 2021, A1M Pharma AB changed name to Guard Therapeutics International AB.

Key facts

Active substance
Recombinant human alpha-1-microglobulin
Intented use
Treatment of pre-eclampsia
Date of designation
04/07/2014
Orphan designation status
Withdrawn
EU designation number
EU/3/14/1289

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Scheelevägen 22
223 63 Lund
Sweden
Tel. +46 46 286 50 30
E-mail: info@guardtherapeutics.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating